

APPENDIX: Clean Copy of Claims

6. (amended) A diagnostic test to predict the risk of developing lupus comprising reagents which can be used to detect levels of antibodies to Epstein-Barr virus, indicators of Epstein-Barr infection of cells, or levels of Epstein-Barr DNA or protein in a patient, and control samples from individuals not at risk of developing lupus, and means for determining the differences in levels of a patient and control samples to distinguish individuals at higher risk of developing lupus from those at lower risk of developing lupus.

7. (amended) The diagnostic test of claim 6 wherein the reagents are used in assays selected from the group of assays based upon the relative presence of an antibody, assays based on cellular proliferation, assays based on molecular binding, assays based on cytokine production, assays based on skin reaction, and assays based on cell surface antigen.

8. (amended) The diagnostic test of claim 6 wherein the reagents used to detect antibodies to peptides from Epstein-Barr virus are selected from the group consisting of PPPGRRP (SEQ ID NO:1), GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3), GAGAGAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7), GPQRRGGDNHGRGRGRGRGGGRPG (SEQ ID NO:98), GGSGSGPRHRDGVRPQKRP (SEQ ID NO:25), RPQKRPSC (SEQ ID NO:26), QKRPSCIGCKGTHGGTG (SEQ ID NO:27), GTGAGAGAGRGRGG (SEQ ID NO:99), SGGRGRGG (SEQ ID NO:100), RGGSGGRRGRGR (SEQ ID NO:101), RARGRGRGRGEKRPRS (SEQ ID NO:102), SSSSGSPPRRPPPGR (SEQ ID NO:103), RPPPGRPFHPVGEADYFEYHQEG (SEQ ID NO:104), PDVPPGAI (SEQ ID NO:33), PGAIEQGPA (SEQ ID NO:34), GPSTGPRG (SEQ ID NO:105), GQGDGGRRK (SEQ ID NO:37), DGGRRKKGGWFGKHR (SEQ ID NO:38), GKHRGQGGSN (SEQ ID NO:106), GQGGSNPK (SEQ ID NO:107), NPKFENIA (SEQ ID NO:108), RSHVERTT (SEQ ID NO:109), VFVYGGSKT (SEQ ID NO:110), GSCTSLYNL (SEQ ID NO:111), GMAPGPGP (SEQ ID NO:46), PQPGPLRE (SEQ ID NO:47), CNIRVTVC (SEQ ID NO:48), RVTVCSFDDG (SEQ ID NO:49), PPWFPPMVEG (SEQ ID NO:50).

9. The diagnostic test of claim 8 comprising reagents for detection of antibodies to GAGAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7).

10. The diagnostic test of claim 6 for testing patients identified with or at risk of developing systemic lupus erythematosus comprising control samples from individuals with systemic lupus erythematosus.

19. (amended) A method for determining the likelihood that an individual has lupus induced by Epstein-Barr virus, or is at risk for developing lupus, comprising obtaining a sample from the individual to be tested,

mixing the sample with reagents which can be used to detect levels of antibodies to Epstein-Barr virus, indicators of Epstein-Barr infection of cells, or levels of Epstein-Barr DNA or protein in a patient,

analyzing the sample, and

comparing the analysis of the sample with results obtained with control samples from individuals not at risk of developing lupus to determine if the differences in levels of the individual and control samples indicates the individual is at a higher risk of developing lupus than controls who are at lower risk of developing lupus.

20. (amended) The method of claim 19 wherein the reagents are used in assays selected from the group of assays based upon the relative presence of an antibody, assays based on cellular proliferation, assays based on molecular binding, assays based on cytokine production, assays based on skin reaction, and assays based on cell surface antigen.

21. (amended) The method of claim 19 wherein the reagents used to detect antibodies to peptides from Epstein-Barr virus are selected from the group consisting of PPPGRRP (SEQ ID NO:1), GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3), GAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7), GPQRRGGDNHGRGRGRGRGGGRPG (SEQ ID NO:98), GGSGSGPRHRDGVRPPQKRP (SEQ ID NO:25), RPQKRPS (SEQ ID NO:26), QKRPSCIGCKGTHGGTG (SEQ ID NO:27), GTGAGAGARGRG (SEQ ID NO:99), SGGRGRGG (SEQ ID NO:100), RGGSGGRRGRGR (SEQ ID NO:101), RARGRGRGRGEKRPRS (SEQ ID NO:102), SSSSGSPPRPPPGR (SEQ ID NO:103), RPPPGRPFHPVGEADYFEYHQEG (SEQ ID NO:104), PDVPPGAI (SEQ ID NO:33), PGAIEQGPA (SEQ ID NO:34), GPSTGPRG (SEQ ID NO:105), GQGDGGRRK (SEQ ID NO:37), DGGRRKKGGWFGKHR (SEQ ID NO:38), GKHRGQGGSN (SEQ ID NO:106),

GQGGSNPK (SEQ ID NO:107), NPKFENIA (SEQ ID NO:108), RSHVERTT (SEQ ID NO:109), VFVYGGSKT (SEQ ID NO:110), GSKTSLYNL (SEQ ID NO:111), GMAPGPGP (SEQ ID NO:46), PQPGPLRE (SEQ ID NO:47), CNIRVTVC (SEQ ID NO:48), RVTVCSFDDG (SEQ ID NO:49), PPWFPPMVEG (SEQ ID NO:50).

22. The method of claim 19 wherein the individual is tested for the presence of antibodies to GAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7).

ATL1 #538648 v1